Table 3.
MiRNA-based Therapy Clinical Trials in the U.S.
| Company | Name | Therapeutic Agent | Delivery System | Condition or Disease | Clinical Phase, Status |
|---|---|---|---|---|---|
| miRagen Therapeutics | MRG-106 | Anti-miR-155 | LNA-antisense | Cutaneous T-cell Lymphoma (CTCL)/Mycosis Fungoides (MF) | Phase II (NCT03837457), Enrolling by invitation |
| Phase I (NCT03713320), Active, not recruiting | |||||
| miRagen Therapeutics | MRG-106 | Anti-miR-155 | LNA-antisense | CTCL, MF, Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-cell Lymphoma (DVBCL), Activated B-cell (ABC) subtype, Adult T-cell Leukemia/Lymphoma (ATLL) | Phase I (NCT02580552), Active, not recruiting |
| Mirna Therapeutics Inc. | MRX-34 | miR-34 mimic | dsRNA liposomal nanoparticle | Melanoma | Phase I (NCT02862145), Withdrawn |
| Mirna Therapeutics Inc. | MRX-34 | miR-34 mimic | dsRNA liposomal nanoparticle | Primary liver cancer, SCLS, Lymphoma, Melanoma, Multiple myeloma, Renal cell carcinoma, NSCLC | Phase I (NCT01829971), Terminated |
| EnGeneIC | MesomiR-1 | miR-16 mimic | EnGeneIC Dream Vector | Malignant pleural mesothelioma, Non-small-cell lung cancer |
Phase I (NCT02369198), Completed |